Pegvisomant

Drug Profile

Pegvisomant

Alternative Names: B2036-PEG; Somavert; Trovert

Latest Information Update: 11 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech; Omeris
  • Developer Pfizer
  • Class Anterior pituitary hormones; Recombinant proteins
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly
  • Discontinued Cancer; Diabetic retinopathy

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 31 Oct 2013 Pfizer completes a phase I trial to asses the pharmacokinetic comparability of pegvisomant doses in healthy volunteers in Belgium (NCT01893866)
  • 27 Aug 2013 Discontinued - Phase-II for Diabetic retinopathy in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top